Drug: Tisagenlecleucel (Kymriah, Novartis)
Status: Approved for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse
Significant Information:
- First chimeric antigen receptor T cell (CAR-T) therapy and first therapy based on gene transfer approved in the United States
- Tisagenlecleucel, formerly called CTL019, is a genetically modified autologous T-cell immunotherapy. It consists of leukapheresed